Argatroban in extracorporeal membrane oxygenation

Area of Science:

• Critical Care Medicine
• Pharmacology
• Hematology

Background:

• Heparin-induced thrombocytopenia (HIT) necessitates alternative anticoagulation strategies.
• Extracorporeal membrane oxygenation (ECMO) requires careful anticoagulation management.
• Direct thrombin inhibitors like argatroban are used in HIT patients.

Purpose of the Study:

• To determine the appropriate dose and anticoagulatory effect of argatroban in patients with suspected HIT undergoing ECMO.
• To evaluate the safety and efficacy of argatroban in this specific patient population.

Main Methods:

• Nine consecutive patients with severe acute respiratory distress syndrome (ARDS) and suspected HIT on ECMO were treated with argatroban infusion.
• Dose adjustments were made to target an activated partial thromboplastin time (aPTT) of 50-60 seconds.
• Coagulation variables, including aPTT and thrombin time, were monitored.

Main Results:

• The manufacturer's recommended dose caused excessive anticoagulation and bleeding in the first patient.
• A 10-fold lower dose (0.2 microg/kg/min) achieved therapeutic anticoagulation, significantly increasing aPTT and thrombin time (P < 0.001).
• No extracorporeal system clotting was observed with the adjusted dose; HIT was confirmed in 33% of patients.

Conclusions:

• Argatroban is a feasible and effective anticoagulant for critically ill patients with suspected HIT undergoing ECMO.
• A significantly lower initial dose of argatroban than recommended is sufficient for safe and effective anticoagulation in this context.
• Careful dose titration is crucial for optimizing argatroban therapy in ECMO patients.